Association for Accessible Medicines Names New President and CEO
Health Care Advocate Dan Leonard Will Lead Generic and Biosimilar Industry Trade Group WASHINGTON, DC (August 25, 2020) – The Association for Accessible Medicines (AAM) Board of Directors today announced the appointment of Dan Leonard to be the association’s President and Chief Executive Officer. Mr. Leonard will join AAM in September. He most recently served […]
Lisa Steelman Joins AAM as Vice President, State Government Affairs
WASHINGTON, DC (August 10, 2020) — Today Lisa Steelman is joining the Association for Accessible Medicines (AAM). As Vice President, State Government Affairs, she serves as a senior strategist and lobbyist in partnership with the Senior Vice President, Government Affairs, Chris Bowlin, and other members of the State Government Affairs team to represent AAM and its […]
Thank you, Desh Bandhu Gupta
We at the Association for Accessible Medicines are proud of our rich heritage. The pioneers who forged our industry deserve to be heralded. Some are still with us; some are gone. Please keep reading about them and their contributions to society. It was three years ago today, June 26, that Dr. Desh Bandhu Gupta passed […]
Thank you, Agnes Varis
We at the Association for Accessible Medicines are proud of our rich heritage. The pioneers who forged our industry deserve to be heralded. Some are still with us; some are gone. Please keep reading about them and their contributions to society. In New York City’s Central Park, near the lower end, is a plaque embedded […]
COVID Response: AAM Board Chair Alok Sonig
AAM Board Chair Alok Sonig at Lupin: “We are working night and day globally across our manufacturing footprint to make sure our essential employees are able to come to our sites… and despite the challenges are able to make the product that is critically needed globally and we are doing that.” #covid19 Learn more: https://bit.ly/COVID-Industry-Response
Thank You, Bill Haddad
We at the Association for Accessible Medicines are proud of our rich heritage. The pioneers who forged our industry deserve to be heralded. Some are still with us; some are gone. Please keep reading about them and their contributions to society. Among his many achievements, William “Bill” Haddad, who died at his home in New […]
AAM Interim CEO Jeff Francer on COVID-19
First in a series, view second. As global public health experts are working to map the spread and impact of the novel coronavirus (COVID-19), AAM will work closely with stakeholders, including the U.S. government, to help ensure that patients in the United States may continue to access FDA-approved generic and biosimilar medicines with the same […]
AAM Statement on Resignation of Chip Davis
WASHINGTON, DC (February 10, 2020)- The Association for Accessible Medicines (AAM), the trade association representing the manufacturers of generic and biosimilar medicines, announced today that Chester “Chip” Davis, Jr. is leaving the organization. Jeffrey Francer, AAM Senior Vice President and General Counsel, will serve as interim CEO while the board determines a permanent replacement. Association […]
AAM Announces 2020 Board of Directors
WASHINGTON, DC (February 6, 2020) —The Association for Accessible Medicines (AAM) announced the election of its 2020 Board of Directors and Officers today. Mr. Alok Sonig, CEO – US Generics and Global Head – Generics R&D & Biosimilars, Lupin Inc. is the 2020 AAM Chair of the Board. AAM also named Ms. Carol Lynch, President, […]
AAM Announces 2020 Associate Members
WASHINGTON, DC (February 6, 2020) — The Association for Accessible Medicines (AAM) is pleased to announce its 2020 Associate Members. Associate Members are entities allied with the interests, needs and policy positions of generic and biosimilar medicine developers. Generic drugs saved the U.S. health system $293 billion in 2018, according to the Generic Drug Access […]
Katherine Michelle Raab Joins AAM as Vice President, Federal Government Affairs
WASHINGTON DC (January 7, 2020) – Today Katherine Michelle Raab is joining the Association for Accessible Medicines (AAM). As a senior strategist and lobbyist, she represents AAM and its member companies’ interests before Congress and the White House. In this role she develops short- and long-term goals in support of the federal affairs strategy and […]
AAM Statement on Nomination of Dr. Stephen Hahn to FDA
WASHINGTON DC (November 1, 2019) – The Association for Accessible Medicines (AAM) welcomes the nomination of Dr. Stephen Hahn to lead the U.S. Food and Drug Administration (FDA). If Dr. Hahn is confirmed, AAM and its member companies stand ready to work with the president, Secretary Azar, Dr. Hahn and the entire FDA team to […]
